<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212495</url>
  </required_header>
  <id_info>
    <org_study_id>dexmedetomidine vs neostigmine</org_study_id>
    <nct_id>NCT03212495</nct_id>
  </id_info>
  <brief_title>Intra-articular Dexmedetomidine Versus Neostigmine After Knee Arthroscopy (a Comparative Study)</brief_title>
  <official_title>Comparison Between Intra-articular Dexmedetomidine and Neostigmine as Adjuvant Analgesics After Knee Arthroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knee arthroscopy is a minimally invasive day case procedure which may be done for diagnosis,
      meniscectomy or debridement. Arthroscopic surgery is associated with a variable degree of
      postoperative pain, which is caused by an irritation of free nerve endings of the synovial
      tissue, anterior fat pad, and joint capsule due to surgical excision and resection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many studies were done using different intra-articular agents as local anesthetics, opioids,
      ketamine and alfa2- adrenergic agonists for prevention and treatment of pain after knee
      surgeries.

      Dexmedetomidine is a potent and highly selective alfa2-adrenoreceptor agonist. It has
      sedative-hypnotic, anxiolytic, analgesic, anesthetic and sympatholytic effects.
      Intra-articular dexmedetomidine was used in several studies to enhance postoperative
      analgesia after knee arthroscopy with an increased time to first analgesic request and a
      decreased need for postoperative analgesia Neostigmine is an anticholinesterase and also has
      antinociceptive effects when administered intrathecally or peripherally.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">November 1, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly allocated to one of two groups each including 50 patients; the group received either intraarticular dexametomidine or neostigmine .</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>, Patients were randomly allocated (using random table assignment) into two groups to receive one of the following intra-articular solutions (prepared by an individual not involved in the study) which were injected into the knee joint through the cannular sheath after withdrawal of camera, by the orthopaedic surgeon (who was also unaware of the nature of the study drugs) before the arthroscope removed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative pain</measure>
    <time_frame>36 hours after the end of the surgery.</time_frame>
    <description>visual analogue pain scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>nausea,vomiting</measure>
    <time_frame>36 hours after the end of the surgery.</time_frame>
    <description>nausea and vomiting scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedation</measure>
    <time_frame>36 hours after the end of the surgery.</time_frame>
    <description>Ramsay sedation score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Knee Injuries</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine (D group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intraarticular administration of dexmedetomidine at the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neostigmine (N group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intraarticular administration of neostigmine at the end of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamedetomidine</intervention_name>
    <description>intraarticular injection of 1Âµg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.</description>
    <arm_group_label>dexmedetomidine (D group)</arm_group_label>
    <other_name>precedex</other_name>
    <other_name>dexamedetomidine Hcl injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine</intervention_name>
    <description>intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.</description>
    <arm_group_label>neostigmine (N group)</arm_group_label>
    <other_name>prostigmine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged above 18 years

          -  scheduled for elective arthroscopic knee surgery under intrathecal anaesthesia

        Exclusion Criteria:

          -  Absolute or relative contraindications for intrathecal anaesthesia,

          -  Allergy for the studied drugs.

          -  Patients having history of cardiovascular, cerebrovascular, and respiratory diseases,

          -  Patients receiving chronic pain treatment or hypertension treated with alfa
             methyldopa, clonidine or beta adrenergic blockers were excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut governorate</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Al-Metwalli RR, Mowafi HA, Ismail SA, Siddiqui AK, Al-Ghamdi AM, Shafi MA, El-Saleh AR. Effect of intra-articular dexmedetomidine on postoperative analgesia after arthroscopic knee surgery. Br J Anaesth. 2008 Sep;101(3):395-9. doi: 10.1093/bja/aen184. Epub 2008 Jun 20.</citation>
    <PMID>18567675</PMID>
  </results_reference>
  <results_reference>
    <citation>Bondok RS, Abd El-Hady AM. Intra-articular magnesium is effective for postoperative analgesia in arthroscopic knee surgery. Br J Anaesth. 2006 Sep;97(3):389-92. Epub 2006 Jul 11.</citation>
    <PMID>16835255</PMID>
  </results_reference>
  <results_reference>
    <citation>Ebert T, Maze M. Dexmedetomidine: another arrow for the clinician's quiver. Anesthesiology. 2004 Sep;101(3):568-70.</citation>
    <PMID>15329580</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ghada Mohammed AboelFadl</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>knee arthroscopy</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>neostigmine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Knee Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

